Evidence map›Paper›PMID 42181295›Full record

ArticleBiological psychiatry global open science2026

Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study.

James A Palmer, Matthew Klein, Dai Wang, Mark E Schmidt, Christine Mazzucco, Dawn F Ionescu, Silke Miller, Qingqin S Li, Arif Khan, Arun Arora and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological psychiatry global open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

James A PalmerJohnson & Johnson, San Diego, California.
Matthew KleinJohnson & Johnson, Titusville, New Jersey.
Dai WangJohnson & Johnson, Raritan, New Jersey.
Mark E SchmidtJohnson & Johnson, Beerse, Belgium.
Christine MazzuccoJohnson & Johnson, Toronto, Ontario, Canada.
Dawn F IonescuJohnson & Johnson, San Diego, California.
Silke MillerJohnson & Johnson, San Diego, California.
Qingqin S LiJohnson & Johnson, Titusville, New Jersey.
Arif KhanNorthwest Clinical Research Center, Bellevue, Washington.
Arun AroraNorthwest Clinical Research Center, Bellevue, Washington.
Wayne C DrevetsJohnson & Johnson, San Diego, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This double-blind, placebo-controlled, phase 2a clinical trial evaluated the efficacy and safety of JNJ-55308942 (zanvipixant), a selective, brain-penetrant P2X7 receptor antagonist, in bipolar depression. Methods: Outpatients ages 18 to 64 years with bipolar I/II disorder, who were experiencing a major depressive episode and carried a specific gain-of-function Results: The mean (SD) change in the MADRS total score from baseline to 6 weeks was -16.0 (10.43) for the JNJ-55308942 group ( Conclusions: While the primary end point was not achieved, clinically meaningful findings in secondary outcomes and a tolerable safety profile warrant further investigation into P2X7 receptor antagonism in bipolar depression.

Indexed as

Bipolar disorderGenetic markersMontgomery–Åsberg Depression Rating ScaleNeuroimmunologyPatient-reported outcomesRandomized clinical trial

Identifiers

PMID42181295
PMCPMC13196505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.